Şunu aradınız:: lumiracoxib (Danca - İngilizce)

lumiracoxib
lumiracoxib

kvinder som anvender lumiracoxib bør ikke amme.
women who use lumiracoxib should not breastfeed.

lumiracoxib udskilles i mælken hos diegivende rotter.
lumiracoxib is excreted in the milk of lactating rats.

elimination lumiracoxib elimineres primært via hepatisk metabolisme.
elimination lumiracoxib is eliminated predominantly via hepatic metabolism.

den gennemsnitlige halveringstid for lumiracoxib er ca.4 timer.
the mean plasma half-life of lumiracoxib is approximately 4 hours.

hver 100 mg filmovertrukken tablet indeholder 100 mg af lumiracoxib.
each 100 mg film-coated tablet contains 100 mg lumiracoxib.

der var ingen signifikante forskelle mellem lumiracoxib og nsaid.
there were no significant differences between lumiracoxib and nsaids.

- anbefaler opfølgningsforanstaltninger til videre undersøgelse af sikkerheden af lumiracoxib.
- recommended follow up measures to further investigate the safety of lumiracoxib.

forsigtighed skal udvises når behandling med lumiracoxib initieres hos dehydrerede patienter.
caution should be used when initiating treatment with lumiracoxib in patients with dehydration.

- kendt overfølsomhed over for lumiracoxib eller over for et eller flere af
- known hypersensitivity to lumiracoxib or to any of the excipients.

Ændringer i oral antikonception er derfor ikke nødvendigt ved samtidig administration af lumiracoxib.
thus no alteration in oral contraceptive medication is necessary when lumiracoxib is co-administered.

5% af den administrerede dosis kunne genfindes i ekskreterne som uomdannet lumiracoxib.
only about 5% of the administered dose was recovered in excreta as unchanged lumiracoxib.

ligesom andre nsaid kan lumiracoxib maskere feber og andre tegn på inflammation eller infektion.
as with other nsaids, lumiracoxib may mask fever and other signs of inflammation or infection.

der er indberettet alvorlige hypersensitivitetsreaktioner (anafylakse, angioødem) hos patienter som fik lumiracoxib.
serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving lumiracoxib.

samtidig administration af lumiracoxib påvirkede ikke steady- state farmakokinetik eller effekt af ethinyløstradiol og levonorgestrel.
co-administration of lumiracoxib did not affect the steady state pharmacokinetics or the efficacy of ethinylestradiol and of levonorgestrel.

databaseundersøgelse af anvendelsen af lumiracoxib og andre markedsførte nsaid’ s og cox- 2- hæmmere.
to conduct a database study of drug utilisation of lumiracoxib and other marketed nsaids and cox-2 inhibitors.

lumiracoxib novartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr storbritannien frexocel novartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr storbritannien frexocel novartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr storbritannien frexocel novartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr storbritannien stellige novartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr storbritannien
novartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr united kingdomnovartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr united kingdomnovartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr united kingdomnovartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr united kingdomnovartis pharmaceuticals uk ltd frimley business park frimley camberley surrey gu16 7sr united kingdom

4'-hydroxy-lumiracoxib, 5 -carboxy-lumiracoxib og 4'-hydroxy-5-carboxy-lumiracoxib.
4'-hydroxy-lumiracoxib, 5-carboxy-lumiracoxib and 4'-hydroxy-5-carboxy-lumiracoxib.

andre lægemidlers effekt på lumiracoxibs fk fluconazol:
effects of other drugs on the pk of lumiracoxib fluconazole: